BioCryst Pharmaceuticals: BCX4430 Non-Human Primate Data Is Encouraging, Says MLV
MLV’s healthcare analyst Vernon Bernardino today weighed in with his thoughts on BioCryst Pharmaceuticals (NASDAQ:BCRX), as the company announced positive results from evaluation of its broad spectrum antiviral, BCX4430, in a model of Ebola virus (EV) infection in a non-human primate (NHP) species (rhesus macaque). The analyst reiterated a Buy rating on BioCryst shares with a $15 price target.
Bernardino observed, “We believe the data replicate prior results with BCX4430 against Marburg virus, another hemorrhagic fever virus, and EV in cynomolgus macaque monkeys, and thus, support continued development of BCX4430, which recently began Phase I evaluation vs. placebo in healthy volunteers. As this program is funded by a grant totaling $28.7MM from the US National Institute of Allergy and Infectious Diseases (NIAID), we look for continued progress with BCX4430 in 2015, and pending demonstration of safety (proj. results 1Q15), anticipate evaluating its market potential at a future date, as BCX4430 is not in our models.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Vernon Bernardino has a total average return of -23.0% and a 20.8% success rate. Bernardino has a -13.4% average return when recommending BCRX, and is ranked #3394 out of 3423 analysts.